Welcome to IntegraGen's News and Events page. Here you will find current and archived press releases, listings of upcoming events, and news coverage about the company and some of its projects and initiatives.

Contact us if you would like more information about IntegraGen and our efforts.

IntegraGen reports 2020 annual results: 10% growth in revenue from current operations and achievement of breakeven operating profits

Bernard Courtieu, CEO of IntegraGen said: “2020 was an exceptional year for IntegraGen in several ways. Commercial activities achieved double-digit growth, results were close to breakeven for the second consecutive year, and the company’s cash position was strengthened, despite the considerable impact of the health crisis.”

Click here to (…)  » 

Technical Brief: Low-Pass Whole Genome Sequencing – Getting more from less

LP-WGS analysis of liquid biopsies (ctDNA) for oncology applications Background

Analysis of circulating tumor DNA (ctDNA) offers great opportunities for cancer research and patient care. There are multiple applications and benefits associated with studying ctDNA including the ability to identify tumor heterogeneity and the detection of somatic mutations unidentified following (…)  » 

IntegraGen Reports Results for 1st Half of 2020

IntegraGen has announced today its financial results for the first half of 2020 with the accounts having been reviewed by the Board of Directors on 17 September 2020.

Company posts positive operating performance (EBITDA) for the second consecutive semester, supported by revenue growth (+5%) and  confirms (…)  » 

COMBINED GENERAL ASSEMBLY

integragen

IntegraGen’s Combined General Assembly for 2020 will be held on September 17, 2020 at 2 p.m. at the company’s headquarters which is located at Génopole Campus 1,Genavenir 8, Porte 840, 5 rue Henri Desbruères – 91000 Evry, France

Click here for more (…)  » 

Agreement to file a friendly takeover bid initiated by ONCODNA on INTEGRAGEN

Agreement to file a friendly takeover bid initiated by ONCODNA on INTEGRAGEN to acquire all outstanding shares at a price of 2.20€ per share. This transaction would bring together OncoDNA’s expertise in oncology precision medicine and IntegraGen’s know-how in DNA sequencing services and bioinformatics analyses. The combination of (…)  »